Abcb5(+) stem cells for treating ocular disease
US-2015374756-A1 · Dec 31, 2015 · US
Modalities for the treatment of degenerative diseases of the retina
US9650607B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9650607-B2 |
| Application number | US-201313858376-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 8, 2013 |
| Priority date | Jan 23, 2004 |
| Publication date | May 16, 2017 |
| Grant date | May 16, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
First claim
Opening claim text (preview).
We claim: 1. A method for treating a retinal disease or condition in a human subject comprising transplanting, into the eye of the human subject, human RPE cells obtained by in vitro differentiation of human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-8I, wherein said RPE cells are disposed on a substrate or matrix, and have a normal karyotype, thereby treating the disease or condition as determined by functional testing. 2. The method of claim 1 , which comprises transplantation of the human RPE cells by vitrectomy surgery into the subretinal space of the eye of the human subject. 3. The method of claim 1 , wherein the method restores visual acuity in the subject. 4. The method of claim 1 , wherein visual acuity is restored to a moderate level. 5. The method of claim 1 , wherein the retinal disease or condition is a condition of retinal degeneration. 6. The method of claim 5 , wherein the condition of retinal degeneration comprises retinitis pigmentosa, RPE detachment, retinal dysplasia, retinal atrophy, retinopathy, or macular dystrophy. 7. The method of claim 5 , wherein the condition of retinal degeneration is macular degeneration. 8. The method of claim 7 , wherein said macular degeneration is age-related macular degeneration. 9. The method of claim 5 , wherein the condition of retinal degeneration is Stargardt disease. 10. The method of claim 5 , which comprises transplantation of the composition by vitrectomy surgery into the subretinal space of the eye of the human subject. 11. The method of claim 5 , wherein the method restores visual acuity in the subject. 12. The method of claim 5 , wherein visual acuity is restored to a moderate level.
Assignees
Inventors
Classifications
Antiglaucoma agents or miotics · CPC title
Ophthalmic agents · CPC title
Anti-Parkinson drugs · CPC title
- C12N5/0621Primary
Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062) · CPC title
Basic fibroblast growth factor (bFGF, FGF-2) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9650607B2 cover?
- This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
- Who is the assignee on this patent?
- Astellas Inst For Regenerative Medicine
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0621. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).